Drugs / 17D Yellow fever vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05332197 | May 2022 → Jun 2023 | yellow fever | London School of Hygiene and Tropical Medicine | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 17D Yellow fever vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05332197 ↗ |
| Modality | Vaccine | “The vaccine to be used in this booster study is the licensed Institut Pasteur de Dakar 17D YF vaccine” NCT05332197 ↗ |
| Route | Subcutaneous | “The standard dose is 0·5 ml and is administered subcutaneously in the deltoid region” NCT05332197 ↗ |